Paper6889461
Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer.
Schilsky RL and 2 others. Cancer Treat Rep, 1982. Cited by 98 papers, by iCite.
Cite this record
ConductScience Library. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Papers, record 6889461. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6889461
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cisplatin | Major topic |
| Magnesium Deficiency | Major topic |
| Testicular Neoplasms | Major topic |
| Dysgerminoma | |
| Follow-Up Studies | |
| Humans | |
| Magnesium | |
| Male | |
| Muscles |
Source PubMed
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 98 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41938717 | Hypomagnesemia Associated with Omeprazole Use in Patients Treated with Platinum Derivatives: An Exploratory Randomized Placebo-Controlled Clinical Trial. | Can J Hosp Pharm | 2026 | https://conductscience.org/library/papers/41938717 | PubMed |
| 41854743 | Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity: A Mechanistic Review. | Kidney360 | 2026 | https://conductscience.org/library/papers/41854743 | PubMed |
| 34278747 | An overview of diagnosis and management of drug-induced hypomagnesemia. | Pharmacol Res Perspect | 2021 | https://conductscience.org/library/papers/34278747 | PubMed |
| 28758697 | Renal toxicity and chemotherapy in children with cancer. | Br J Clin Pharmacol | 2017 | https://conductscience.org/library/papers/28758697 | PubMed |
| 27281266 | Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy. | Am J Clin Oncol | 2018 | https://conductscience.org/library/papers/27281266 | PubMed |
| 27057522 | Effect of Oral Magnesium Oxide Supplementation on Cisplatin-Induced Hypomagnesemia in Cancer Patients: A Randomized Controlled Trial. | Iran J Public Health | 2016 | https://conductscience.org/library/papers/27057522 | PubMed |
| 24278698 | Membrane transporters as mediators of Cisplatin effects and side effects. | Scientifica (Cairo) | 2012 | https://conductscience.org/library/papers/24278698 | PubMed |
| 21505757 | Does cisplatin-based chemotherapy effect on blood lipid levels of patients with germ cell testicular tumor in long-term follow-up? | Int Urol Nephrol | 2011 | https://conductscience.org/library/papers/21505757 | PubMed |
| 19629622 | Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. | Clin Exp Nephrol | 2009 | https://conductscience.org/library/papers/19629622 | PubMed |
| 17848741 | Long-term complications of platinum-based chemotherapy in testicular cancer survivors. | Med Oncol | 2007 | https://conductscience.org/library/papers/17848741 | PubMed |
| 16205699 | The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. | Br J Cancer | 2005 | https://conductscience.org/library/papers/16205699 | PubMed |
| 16119971 | Drug-induced hypomagnesaemia : scope and management. | Drug Saf | 2005 | https://conductscience.org/library/papers/16119971 | PubMed |
| 9635848 | Cisplatin dose rate as a risk factor for nephrotoxicity in children. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9635848 | PubMed |
| 8980410 | Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8980410 | PubMed |
| 8573296 | Comparative adverse effect profiles of platinum drugs. | Drug Saf | 1995 | https://conductscience.org/library/papers/8573296 | PubMed |
| 7807572 | Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part II. | J Natl Med Assoc | 1994 | https://conductscience.org/library/papers/7807572 | PubMed |
| 3918779 | A clinical approach to common electrolyte problems: 4. Hypomagnesemia. | Can Med Assoc J | 1985 | https://conductscience.org/library/papers/3918779 | PubMed |
| 3524645 | Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. | Br J Cancer | 1986 | https://conductscience.org/library/papers/3524645 | PubMed |
| 2875808 | Cumulative renal tubular damage associated with cisplatin nephrotoxicity. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/2875808 | PubMed |
| 2731311 | Does parenteral magnesium sulfate have an antiemetic effect during chemotherapy with cis-platinum? | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2731311 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6889461
GET https://conductscience.org/api/papers/v1/6889461/cited_by?page=2